PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
Both companies reducing costs. Martin Whitman would check industry efficiency trends.
41.00%
Growth of 41.00% while TRAW shows flat gross profit. Bruce Berkowitz would examine quality advantage.
No Data
No Data available this quarter, please select a different quarter.
-31.86%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-15.50%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.75%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-27.36%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
Both companies reducing D&A. Martin Whitman would check industry patterns.
28.32%
EBITDA growth exceeding 1.5x TRAW's 12.31%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
27.93%
Operating income growth exceeding 1.5x TRAW's 12.32%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-5.21%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
29.77%
Pre-tax income growth exceeding 1.5x TRAW's 11.71%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
128.31%
Tax expense growth while TRAW reduces burden. John Neff would investigate differences.
29.77%
Net income growth exceeding 1.5x TRAW's 11.71%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
30.61%
EPS growth exceeding 1.5x TRAW's 13.04%. David Dodd would verify competitive advantages.
30.61%
Diluted EPS growth exceeding 1.5x TRAW's 13.04%. David Dodd would verify competitive advantages.
2.13%
Share count reduction below 50% of TRAW's 0.00%. Michael Burry would check for concerns.
2.13%
Diluted share reduction below 50% of TRAW's 0.00%. Michael Burry would check for concerns.